Tuesday, November 5, 2024
Subscribe American Journal of Medicine Free Newsletter
diagnostic testsPolymyalgia Rheumatica with Normal Inflammatory Markers

Polymyalgia Rheumatica with Normal Inflammatory Markers

PET/CT images showing increased 18F-fluorodeoxyglucose uptake that was consistent with a diagnosis of polymyalgia rheumatica. (A) Shoulders (blue arrows) and peritrochanteric bursae at hip joints (green arrows). (B) Greater trochanter (red arrows) and ischial tuberosities (yellow arrows).
PET/CT images showing increased 18F-fluorodeoxyglucose uptake that was consistent with a diagnosis of polymyalgia rheumatica. (A) Shoulders (blue arrows) and peritrochanteric bursae at hip joints (green arrows). (B) Greater trochanter (red arrows) and ischial tuberosities (yellow arrows).

A 70-year-old man presented with pain in his shoulders, low back, and thighs for 1 year. He had difficulties when changing clothes, taking a bath, and getting out of bed because all these body movements aggravated the pain. He also experienced morning stiffness for 1 hour. Although his weight decreased by 5 kg because of loss of appetite, he denied any nausea, diarrhea, depressed mood, fever, headache, visual disturbance, or jaw claudication. His medical history included diabetes mellitus with maintained hemoglobin A1c levels of <7% and dyslipidemia, for which he was taking 50 mg sitagliptin, 0.5 mg glimepiride, 750 mg metformin, and 2.5 mg rosuvastatin daily.

On physical examinations, he could neither raise his arms nor squat down because of pain, but his muscle strength was normal. None of his muscles and joints had redness, swelling, warmth, or tenderness. He had no tenderness on temporal or occipital arteries. Laboratory test results revealed mild normocytic anemia (13.0 g/dL of hemoglobin level and 87 fL of mean corpuscular volume) with a low level of serum iron (50 µg/dL). C-reactive protein (0.1 mg/dL), erythrocyte sedimentation rate (10 mm/h), and ferritin (86 ng/mL) levels were all normal.

All additional tests showed normal results, including adrenocorticotropic hormone and cortisol by an adrenocorticotropic hormone stimulation test, rheumatoid factor, anti-cyclic citrullinated peptide antibody, anti-nuclear antibody, and anti-neutrophil cytoplasmic antibody. Upper and lower endoscopies detected no abnormal findings. Ultrasound showed bilateral biceps tenosynovitis. Positron emission tomography (PET)/computed tomography (CT) revealed no malignancy or vasculitis, but 18F-fluorodeoxyglucose uptake was seen in the bilateral shoulders, hip joints, greater trochanter of femurs, and ischial tuberosities without any bone erosion (Figure). The pain did not improve after ceasing sitagliptin for more than 1 month. Although normal levels of C-reactive protein and erythrocyte sedimentation rate did not meet the criteria for polymyalgia rheumatica of the European League Against Rheumatism and the American College of Rheumatology in 2012, bilateral shoulder pain in patients who were aged >50 years, morning stiffness for >45 minutes, hip pain and limited range of movement, absence of rheumatoid factor and anti-cyclic citrullinated peptide antibody, and ultrasound findings in addition to PET/CT findings indicated a diagnosis of polymyalgia rheumatica. A prescription of 15 mg oral prednisolone improved his pain immediately, and this dosage was subsequently decreased to <5 mg over 1 year without relapse.
Polymyalgia rheumatica is a relatively common inflammatory disease in elderly individuals that mimics other conditions, including malignancy, infections, and rheumatic disorders.1 Although 7% to 20% of patients show low erythrocyte sedimentation rate in polymyalgia rheumatica, other diagnoses must be considered in patients with normal C-reactive protein in addition to low erythrocyte sedimentation rate for the rarity of such a condition.1 As one of the alternative disorders, drug-induced arthritis can be caused by antimicrobials, dipeptidyl peptidase-4 inhibitors, chemotherapeutics, retinoids, cytokines, and psychotropics.2 Because dipeptidyl peptidase-4 inhibitors, including sitagliptin, that our patient was taking can induce polyarthritis with normal inflammatory markers, these suspected drugs should be ceased for more than 1 month to exclude them as a causative factor. Another important differential diagnosis should be adrenal deficiency. It can cause muscle pain, arthralgia, low back pain, and limited range of movement,3 which are similar symptoms to polymyalgia rheumatica, with normal inflammatory markers. Moreover, because adrenal deficiency improves rapidly with low-dose steroid similar to polymyalgia rheumatica, a hormonal test should be done before trying treatment with prednisolone. Rheumatoid arthritis is a major mimic of polymyalgia rheumatica, and some patients show normal inflammatory markers. However, elderly-onset rheumatoid arthritis with polymyalgia rheumatic-like symptoms has a high level of C-reactive protein compared with those without polymyalgia rheumatica-like symptoms.4 PET/CT would play a significant role to exclude mimics and to detect polymyalgia rheumatica.

To read this article in its entirety please visit our website.

-Shingo Suzuki, MD, PhD, Yuta Hirose, MD, Eriko Takeda, MD, Masatomi Ikusaka, MD, PhD

This article originally appeared in the July issue  of The American Journal of Medicine.

Latest Posts

lupus

Sarcoidosis with Lupus Pernio in an Afro-Caribbean Man

A 54-year-old man of Afro-Caribbean ancestry presented with a 2-month history of nonproductive cough, 10-day history of constant subjective fevers, and a 1-day history...
Flue Vaccine

Flu Vaccination to Prevent Cardiovascular Mortality (video)

0
"Influenza can cause a significant burden on patients with coronary artery disease," write Barbetta et al in The American Journal of Medicine. For this...
varicella zoster

Varicella Zoster Virus-Induced Complete Heart Block

0
Complete heart block is usually caused by chronic myocardial ischemia and fibrosis but can also be induced by bacterial and viral infections. The varicella...
Racial justice in healthcare

Teaching Anti-Racism in the Clinical Environment

0
"Teaching Anti-Racism in the Clinical Environment: The Five-Minute Moment for Racial Justice in Healthcare" was originally published in the April 2023 issue of The...
Invisible hand of the market

The ‘Invisible Hand’ Doesn’t Work for Prescription Drugs

0
Pharmaceutical innovation has been responsible for many “miracles of modern medicine.” Reliance on the “invisible hand” of Adam Smith to allocate resources in the...
Joseph S. Alpert, MD

New Coronary Heart Disease Risk Factors

0
"New Coronary Heart Disease Risk Factors" by AJM Editor-in Chief Joseph S. Alpert, MD was originally published in the April 2023 issue of The...
Cardiovascular risk from noncardiac activities

Cardiac Risk Related to Noncardiac & Nonsurgical Activities

0
"Assessment of Cardiovascular Risk for Noncardiac and Nonsurgical Activities" was originally published in the April 2023 issue of The American Journal of Medicine. Cardiovascular risk...